Adam Feinberg is a Professor in the Departments of Biomedical Engineering and Materials Science and Engineering at Carnegie Mellon University (CMU). He leads the Regenerative Biomaterials & Therapeutics Group, focusing on cell-material interactions, 3D bioprinting, and bioengineered tissues. His work integrates nanofabrication, molecular biology, and 3D imaging to address challenges in muscle repair, corneal regeneration, and cancer. Key innovations include the FRESH bioprinting platform, enabling soft ECM gel-based constructs, and ECM shrink-wrapping techniques for cell encapsulation. Feinberg holds a Ph.D. and MS in Biomedical Engineering from the University of Florida (2004, 2002) and a BS in Materials Science and Engineering from Cornell University (1999). He has secured major grants, including ARPA-H funding for diabetes treatments and Canada’s New Frontiers Fund for heart disease therapies. His research has led to over 45 peer-reviewed articles and 20 patents. His scientific awards include the NIH Director’s New Innovator Award and NSF CAREER Award. Media highlights include breakthroughs in vascularized tissue models and biodegradable actuators. Feinberg collaborates widely, advancing clinical translation of bioprinted tissues and sustainable bio-bots.








